Upgrade group n=22 de Novo group n=71
p
Heart failure etiology
Chagas, n (%) 16 (72.7%) 13 (18.3%) <0.001
Idiopathic, n (%) 1 (4.5%) 27 (38.0%) 0.003
Ischemic, n (%) 1 (4.5%) 14 (19.7%) 0.109
Age, years (±SD) 62.4 (±13.8) 56.6 (±11.4) 0.080
Male gender, n (%) 15 (68.2%) 36 (50.7%) 0.220
LVEF, mean (±SD) 22.3 (±7.1) 24.4 (±7.6) 0.249
NYHA class III or IV, n (%) 19 (86.4%) 57 (80.3%) 0.754
Atrial fibrillation, n (%) 5 (22.7%) 15 (21.1%) 1.000
QRS > 150ms, n (%) 21 (95.5%) 64 (90.1%) 0.675
QRS duration, mean (±SD) 158.2 (±14.7) 160.1 (±22.5) 0.636
non-LBBB, n (%) 1 (4.5%) 5 (7.0%) 1.000
Myocardial infarction, n (%) 2 (9.1%) 10 (14.1%) 0.725
Stroke, n (%) 3 (13.6%) 4 (5.6%) 0.350
Hemoglobin, g/dL (±SD) 11.8 (±3.1) 12.8 (±1.8) 0.147
Chronic kidney disease, n (%) 8 (36.4%) 17 (23.9%) 0.278
Diabetes, n (%) 7 (31.8%) 23 (32.4%) 1.000
Medications
ACEI, ARB or ARNI 20 (90.9%) 61 (85.9%) 0.725
Beta-blocker 21 (95.5%) 65 (91.5%) 1.000
Spironolactone 18 (81.8%) 63 (88.7%) 0.469